Log in

NASDAQ:BASIBioanalytical Systems Stock Price, Forecast & News

$4.87
-0.30 (-5.80 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.75
Now: $4.87
$5.23
50-Day Range
$4.65
MA: $5.16
$5.40
52-Week Range
$1.95
Now: $4.87
$6.50
Volume20,400 shs
Average Volume16,411 shs
Market Capitalization$52.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BASI
CUSIPN/A
Phone765-463-4527

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.62 million
Cash Flow$0.21 per share
Book Value$1.02 per share

Profitability

Net Income$-790,000.00

Miscellaneous

Employees224
Market Cap$52.89 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive BASI News and Ratings via Email

Sign-up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter.

Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions

How has Bioanalytical Systems' stock been impacted by COVID-19 (Coronavirus)?

Bioanalytical Systems' stock was trading at $4.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BASI stock has increased by 13.0% and is now trading at $4.87. View which stocks have been most impacted by Coronavirus.

When is Bioanalytical Systems' next earnings date?

Bioanalytical Systems is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Bioanalytical Systems.

How were Bioanalytical Systems' earnings last quarter?

Bioanalytical Systems, Inc. (NASDAQ:BASI) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $16.01 million for the quarter. Bioanalytical Systems had a negative net margin of 3.94% and a negative return on equity of 12.39%. View Bioanalytical Systems' earnings history.

Has Bioanalytical Systems been receiving favorable news coverage?

Headlines about BASI stock have been trending somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bioanalytical Systems earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Bioanalytical Systems.

Are investors shorting Bioanalytical Systems?

Bioanalytical Systems saw a decrease in short interest in June. As of June 30th, there was short interest totaling 12,400 shares, a decrease of 6.1% from the June 15th total of 13,200 shares. Based on an average daily trading volume, of 16,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.2% of the shares of the stock are short sold. View Bioanalytical Systems' Current Options Chain.

Who are some of Bioanalytical Systems' key competitors?

What other stocks do shareholders of Bioanalytical Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioanalytical Systems investors own include Athersys (ATHX), NovaBay Pharmaceuticals (NBY), Exxon Mobil (XOM), Enphase Energy (ENPH), Energy Recovery (ERII), GASTAR EXPL INC/SH (GST), Idera Pharmaceuticals (IDRA), Lattice Semiconductor (LSCC), Luna Innovations (LUNA) and Overstock.com (OSTK).

Who are Bioanalytical Systems' key executives?

Bioanalytical Systems' management team includes the following people:
  • Mr. Philip A. Downing, Sr. VP of Preclinical Services (Age 49)
  • Ms. Jill C. Blumhoff, CFO, VP of Fin. & Sec. (Age 43)
  • Mr. Robert Leasure Jr., Pres, CEO & Director (Age 59)
  • Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 74)
  • Mr. D. Thomas Oakley, Chief Operating Officer

What is Bioanalytical Systems' stock symbol?

Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI."

How do I buy shares of Bioanalytical Systems?

Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bioanalytical Systems' stock price today?

One share of BASI stock can currently be purchased for approximately $4.87.

How big of a company is Bioanalytical Systems?

Bioanalytical Systems has a market capitalization of $52.89 million and generates $43.62 million in revenue each year. Bioanalytical Systems employs 224 workers across the globe.

What is Bioanalytical Systems' official website?

The official website for Bioanalytical Systems is www.basinc.com.

How can I contact Bioanalytical Systems?

Bioanalytical Systems' mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at 765-463-4527 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.